{"entity":{"id":"eortc-22033","kind":"trial","name":"EORTC 22033-26033","aka":[],"tldr":"EORTC 22033 asked whether temozolomide could replace radiotherapy as the first treatment for high-risk low-grade glioma and found no difference in progression-free survival, with the molecular subtype mattering more than the choice of treatment.","summary":"EORTC 22033-26033 randomised 477 adults with high-risk low-grade glioma to 50.4 Gy radiotherapy or dose-dense temozolomide for up to a year. Median progression-free survival was 46 months with radiotherapy and 39 months with temozolomide (hazard ratio 1.16, not significant); IDH-mutant tumours without 1p/19q co-deletion did better with radiotherapy, and health-related quality of life did not differ (Baumert and colleagues, Lancet Oncology 2016). Radiotherapy followed by chemotherapy (as in RTOG 9802) remains the standard.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT00182819","url":"https://clinicaltrials.gov/study/NCT00182819"},{"label":"Lancet Oncology 2016","url":"https://doi.org/10.1016/S1470-2045(16)30313-8"}],"tags":["radiation-wave4"],"related":[],"cancers":["glioblastoma","brain-tumours","idh-mutant-astrocytoma","oligodendroglioma"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["temozolomide"],"companies":["curie-nki-eortc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-baumert-lancet-oncol"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00182819","phase":"3","setting":"High-risk low-grade glioma: radiotherapy versus temozolomide alone as first treatment","sponsor":"EORTC","result":"Median progression-free survival 46 (radiotherapy) vs 39 months (temozolomide), no significant difference.","started":"2005-07","yearReported":2016,"enrolled":477,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Radiotherapy (50.4 Gy)","n":240,"value":46},{"name":"Dose-dense temozolomide","n":237,"value":39}],"hr":1.16,"ci":[0.9,1.5],"p":"0.22","source":"https://doi.org/10.1016/S1470-2045(16)30313-8"}]},"route":"/trials/eortc-22033/","neighbours":{"cancer":[{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/"},{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"curie-nki-eortc","kind":"company","name":"EORTC","route":"/companies/curie-nki-eortc/"}],"paper":[{"id":"paper-baumert-lancet-oncol","kind":"paper","name":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","route":"/key-papers/paper-baumert-lancet-oncol/"}]}}